- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06698887
A Study to Evaluate the Long-Term Safety of Idecabtagene Vicleucel Treatment in Adults With Newly Diagnosed Multiple Myeloma in Korea
Long-Term Safety Follow-Up Surveillance for Phase 3 Trial (KarMMA-9/CA089-1043) to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
The purpose of this study is to monitor the long-term safety of participants who received idecabtagene vicleucel treatment as part of the KarMMa-9 (CA089-1043) Phase 3 clinical trial.
Study Overview
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: BMS Study Connect Contact Center www.BMSStudyConnect.com
- Phone Number: 855-907-3286
- Email: Clinical.Trials@bms.com
Study Contact Backup
- Name: First line of the email MUST contain NCT # and Site #.
Study Locations
-
-
Jeonranamdo
-
Hwasun, Jeonranamdo, South Korea, 58128
- Recruiting
- Chonnam National University Hwasun Hospital
-
Contact:
- Sung Hoon Jung, Site 0041
- Phone Number: 82613797623
-
-
Seoul-teukbyeolsi [Seoul]
-
Seoul, Seoul-teukbyeolsi [Seoul], South Korea, 03080
- Recruiting
- Seoul National University Hospital
-
Contact:
- SungSoo Yoon, Site 0039
- Phone Number: 82-2-2072-3079
-
Seoul, Seoul-teukbyeolsi [Seoul], South Korea, 06351
- Recruiting
- Samsung Medical Center
-
Contact:
- Kihyun Kim, Site 0038
- Phone Number: +821099333456
-
Seoul, Seoul-teukbyeolsi [Seoul], South Korea, 05505
- Recruiting
- Asan Medical Center
-
Contact:
- Dok Hyun Yoon, Site 0040
- Phone Number: 82230105940
-
Seoul, Seoul-teukbyeolsi [Seoul], South Korea, 06591
- Recruiting
- The Catholic Univ. of Korea Seoul St. Mary's Hospital
-
Contact:
- Chang Ki Min, Site 0043
- Phone Number: 82-20-2258-6053
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Adult participants with newly diagnosed multiple myeloma (NDMM) who had a suboptimal response after autologous stem cell transplantation (ASCT) and who were treated with idecabtagene vicleucel in the KarMMa-9 (CA089-1043) Phase 3 clinical trial.
Description
Inclusion Criteria:
- Adult participants ≥19 years of age
- Korean participants with newly diagnosed multiple myeloma who had a suboptimal response after autologous stem cell transplantation (ASCT) and who were treated with idecabtagene vicleucel (assigned to Arm A) in the KarMMa-9 trial (CA089-1043)
- Participants must understand and voluntarily sign and informed consent form (ICF) for the Korea long-term follow-up surveillance study prior to any surveillance-related procedures being conducted
Exclusion Criteria:
- Participants who participate in KarMMa-9 trial (CA089-1043) but disagree with long-term follow-up surveillance in Korea
- Participants who are not possible to treat with Ide-cel within 9 days post-completion of lymphodepleting chemotherapy (LDC), if delays occur. However, depending on the participants recovery status, whether idecabtagene vicleucel is administered or not, should be discussed with a medical monitor
Study Plan
How is the study designed?
Design Details
- Observational Models: COHORT
- Time Perspectives: PROSPECTIVE
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Participants receiving idecabtagene vicleucel
|
As per CA089-1043 study protocol |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Participant adverse events
Time Frame: Monthly from months 4-18, every 2 months from months 19-59, and annually from month year 5 to 15
|
Monthly from months 4-18, every 2 months from months 19-59, and annually from month year 5 to 15
|
|
Number of participants with positive replication-competent lentivirus test results
Time Frame: At 4, 7, 13, and 25 months, and annually up to 15 years
|
At 4, 7, 13, and 25 months, and annually up to 15 years
|
|
Persistent vector sequence monitoring
Time Frame: Months 7-18 and annually from years 5-15
|
Months 7-18 and annually from years 5-15
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Progression-free survival (PFS)
Time Frame: Monthly up to 18 months and every two months after month 19 up to 15 years
|
Monthly up to 18 months and every two months after month 19 up to 15 years
|
|
Overall survival (OS)
Time Frame: Every 3 months up to month 60, annually thereafter up to 15 years
|
Every 3 months up to month 60, annually thereafter up to 15 years
|
|
Number of participants that achieve complete response or stringent complete response
Time Frame: At months 4-18, every 2 months from months 19-59, and annually from years 5-15
|
At months 4-18, every 2 months from months 19-59, and annually from years 5-15
|
|
Health-related quality of life (HRQoL) measured by the European Organization for Research and Treatment of Cancer core quality of life (EORTC QLQ-C30) questionnaire
Time Frame: At months 4-18, every 2 months from months 19-59, and annually from years 5-15
|
At months 4-18, every 2 months from months 19-59, and annually from years 5-15
|
|
Health-related quality of life (HRQoL) measured by the European Organization for Research and Treatment of Cancer assessment of quality of life of myeloma patients (EORTC QLQ-MY20) questionnaire
Time Frame: At months 4-18, every 2 months from months 19-59, and annually from years 5-15
|
At months 4-18, every 2 months from months 19-59, and annually from years 5-15
|
|
Health-related quality of life (HRQoL) measured by the EuroQol-5 Dimensions-5 Levels (EQ-5D-5L) questionnaire
Time Frame: At months 4-18, every 2 months from months 19-59, and annually from years 5-15
|
At months 4-18, every 2 months from months 19-59, and annually from years 5-15
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Bristol-Myers Squibb, Bristol-Myers Squibb
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Vascular Diseases
- Cardiovascular Diseases
- Neoplasms
- Immune System Diseases
- Neoplasms by Histologic Type
- Hematologic Diseases
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Neoplasms, Plasma Cell
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Hemorrhagic Disorders
- Hemic and Lymphatic Diseases
- Multiple Myeloma
- idecabtagene vicleucel
Other Study ID Numbers
- CA089-1081
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.